SCHEMBL7028323

SCHEMBL7028323

O=S(=O)(c1cccc2c(Cl)cccc12)N1CCN(CCc2ccc(F)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
MAPK1 P28482 2/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
NFKB1 P19838 1/20 0.49
MYLK Q15746 1/20 0.49
GMNN O75496 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
PMP22 Q01453 1/20 0.48
PKM P14618 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR2A P28223 2/20 0.45
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7029577 0.87 GPR183 (0.54) MEN1KMT2ATP53LMNAMAPT
SCHEMBL7031186 0.84 KMT2A (0.60) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL7030762 0.81 KMT2A (0.52) MEN1KMT2AMAPK1PKMHTR2A
SCHEMBL7027414 0.80 MEN1 (0.48) MEN1KMT2APKMSMN1; SMN2HTR2A
SCHEMBL7031076 0.80 KMT2A (0.43) MEN1KMT2AMAPTPKMSMN1; SMN2
SCHEMBL7027996 0.80 MEN1 (0.49) MEN1KMT2APKMHTR2AKCNH2
SCHEMBL7029110 0.79 PRKD3 (0.57) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7026165 0.77 KCNH2 (0.69) MEN1KMT2APKMSMN1; SMN2HTR2A
SCHEMBL7022823 0.77 PKM (0.64) POLBMEN1KMT2AMAPK1LMNA
SCHEMBL7027668 0.76 FABP1 (0.65) MAPK1MAPTPKMHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130287-A1 Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists MERCK PATENT GMBH (DE) 2003-07-10 US disclosed
EP-1246803-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT 2A? RECEPTOR ANTAGONISTS MERCK PATENT GmbH (DE) 2002-10-09 EP disclosed
WO-2001051469-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT2A RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130287-A1 Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists HTR2A, HTR1A, HTR5A POLB 1282/4885MEN1 3253/4885KMT2A 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.